A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease
Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…Bidirectional Relationships Between Frailty and DNAm Age Acceleration and its Mediation Effects on Physical Disability and Mortality
Objective: This study aims to investigate the bidirectional associations between frailty and DNA methylation (DNAm) age acceleration (AgeAccel), and further test whether epigenetic aging mediates…PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To evaluate the effect of prasinezumab on slowing down disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab…Neuroprotective Role of Diosgenin-Loaded Lipid Nanoparticles for Parkinson’s Disease: Pharmacokinetic and Pharmacodynamic Insights
Objective: To develop, optimize, and evaluate diosgenin-loaded solid lipid nanoparticles (DG-SLNs) and nanostructured lipid carriers (DG-NLCs) incorporated into hydrogel formulations (DG-SLN-C and DG-NLC-C) for improved…Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies
Objective: Immunotherapy against α-synuclein is a promising novel treatment strategy for Parkinson's disease and related α-synucleinopathies. We have developed exidavnemab (BAN0805), a monoclonal antibody with…Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.
Objective: To perform a systematic review and meta-analysis on recruitment of people with Parkinson’s disease (PwP, PD) from different ethnic and racial groups in disease-modifying…Chronic Sleep Fragmentation Accelerates the Onset of Prodromal Symptoms and Pathology in Parkinson’s Disease Model Mice
Objective: To investigate whether chronic sleep fragmentation accelerates the onset of prodromal symptoms and pathology of Parkinson’s disease (PD) in mice. Background: The prodromal phase…ilex Paraguariensis (Yerba mate) modulates the AMPK pathway and downstream key metabolic mechanism that may explain its neuroprotective role.
Objective: To investigate the molecular pathways regulated by yerba mate [YM] extract and its main active compounds in a neuronal cell line as a cue…Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease
Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 22
- Next Page »